Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission

C. Deng, E. Goluszko, B. Wu, S. Baron, V. Dedhia, P. Christadoss

Research output: Contribution to journalArticle

Abstract

Treatment of mice with established autoimmunity to acetylcholine receptor (AChR) with interferon a (EFNα) suppressed experimental autoimmune myasthenia gravis (EAMG) (Shenoy et al, J. Immunology, 154:6203, 1995). To study the therapeutic efficacy of IFNα after the established clinical signs, we treated mice with established EAMG with mouse IFNα (mIFNα) or human recombinant IFNα (HurlFNα). In experiment I, mIFNα ICPU and in experiment II, HurlFNα 104 U was ?iven intraperitoneal 3 times a week for 6 weeks. In experiment 1,6 of 8 (33%) mice had a complete clinical remission or significant improvement in IFNα group, while only 1 of 17 (6%) mice improved in PBS group, p=0.047; more mice died or worsened in PBS group (11/17) compared to IFNα group (8/18); In experiment II, 7 of 16 (44%) mice had a complete remission or significant improvement in IFNα group, in contrast to only 1 of 14 (7%) in PBS group, p=0.027; also more mice died or worsened in PBS group (6/14) than in IFNα group (4/16). IFNα treatment reduced the MHC class II expression on peripheral blood lymphocytes, and lowered the serum IFNγ level. IFNα in vitro also suppressed AChR and its dominant peptide a!46-162 specific lymphocyte proliferation. Therefore, IFNα, one of the very few treatments which exerts a therapeutic effect on EAMG, is associated with down regulation of IFNγ, MHC class II, and lymphocyte activation. Supported by MDA,Myasthenia Gravis Foundation Osserman postdoctoral fellow.J.W.McLaughlin postdoctoral fellow.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number6
StatePublished - 1996

Fingerprint

Autoimmune Experimental Myasthenia Gravis
remission
interferons
Interferons
Lymphocytes
therapeutics
mice
Cholinergic Receptors
Experiments
Immunology
cholinergic receptors
Therapeutics
lymphocyte proliferation
Blood
Chemical activation
Peptides
autoimmunity
Myasthenia Gravis
Therapeutic Uses
Lymphocyte Activation

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Deng, C., Goluszko, E., Wu, B., Baron, S., Dedhia, V., & Christadoss, P. (1996). Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission. FASEB Journal, 10(6).

Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission. / Deng, C.; Goluszko, E.; Wu, B.; Baron, S.; Dedhia, V.; Christadoss, P.

In: FASEB Journal, Vol. 10, No. 6, 1996.

Research output: Contribution to journalArticle

Deng, C, Goluszko, E, Wu, B, Baron, S, Dedhia, V & Christadoss, P 1996, 'Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission', FASEB Journal, vol. 10, no. 6.
Deng, C. ; Goluszko, E. ; Wu, B. ; Baron, S. ; Dedhia, V. ; Christadoss, P. / Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission. In: FASEB Journal. 1996 ; Vol. 10, No. 6.
@article{6a4b643830b2476d993d5c3aaa3577d7,
title = "Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission",
abstract = "Treatment of mice with established autoimmunity to acetylcholine receptor (AChR) with interferon a (EFNα) suppressed experimental autoimmune myasthenia gravis (EAMG) (Shenoy et al, J. Immunology, 154:6203, 1995). To study the therapeutic efficacy of IFNα after the established clinical signs, we treated mice with established EAMG with mouse IFNα (mIFNα) or human recombinant IFNα (HurlFNα). In experiment I, mIFNα ICPU and in experiment II, HurlFNα 104 U was ?iven intraperitoneal 3 times a week for 6 weeks. In experiment 1,6 of 8 (33{\%}) mice had a complete clinical remission or significant improvement in IFNα group, while only 1 of 17 (6{\%}) mice improved in PBS group, p=0.047; more mice died or worsened in PBS group (11/17) compared to IFNα group (8/18); In experiment II, 7 of 16 (44{\%}) mice had a complete remission or significant improvement in IFNα group, in contrast to only 1 of 14 (7{\%}) in PBS group, p=0.027; also more mice died or worsened in PBS group (6/14) than in IFNα group (4/16). IFNα treatment reduced the MHC class II expression on peripheral blood lymphocytes, and lowered the serum IFNγ level. IFNα in vitro also suppressed AChR and its dominant peptide a!46-162 specific lymphocyte proliferation. Therefore, IFNα, one of the very few treatments which exerts a therapeutic effect on EAMG, is associated with down regulation of IFNγ, MHC class II, and lymphocyte activation. Supported by MDA,Myasthenia Gravis Foundation Osserman postdoctoral fellow.J.W.McLaughlin postdoctoral fellow.",
author = "C. Deng and E. Goluszko and B. Wu and S. Baron and V. Dedhia and P. Christadoss",
year = "1996",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Interferon a therapy for established clinical experimental autoimmune myasthenia gravis induces remission

AU - Deng, C.

AU - Goluszko, E.

AU - Wu, B.

AU - Baron, S.

AU - Dedhia, V.

AU - Christadoss, P.

PY - 1996

Y1 - 1996

N2 - Treatment of mice with established autoimmunity to acetylcholine receptor (AChR) with interferon a (EFNα) suppressed experimental autoimmune myasthenia gravis (EAMG) (Shenoy et al, J. Immunology, 154:6203, 1995). To study the therapeutic efficacy of IFNα after the established clinical signs, we treated mice with established EAMG with mouse IFNα (mIFNα) or human recombinant IFNα (HurlFNα). In experiment I, mIFNα ICPU and in experiment II, HurlFNα 104 U was ?iven intraperitoneal 3 times a week for 6 weeks. In experiment 1,6 of 8 (33%) mice had a complete clinical remission or significant improvement in IFNα group, while only 1 of 17 (6%) mice improved in PBS group, p=0.047; more mice died or worsened in PBS group (11/17) compared to IFNα group (8/18); In experiment II, 7 of 16 (44%) mice had a complete remission or significant improvement in IFNα group, in contrast to only 1 of 14 (7%) in PBS group, p=0.027; also more mice died or worsened in PBS group (6/14) than in IFNα group (4/16). IFNα treatment reduced the MHC class II expression on peripheral blood lymphocytes, and lowered the serum IFNγ level. IFNα in vitro also suppressed AChR and its dominant peptide a!46-162 specific lymphocyte proliferation. Therefore, IFNα, one of the very few treatments which exerts a therapeutic effect on EAMG, is associated with down regulation of IFNγ, MHC class II, and lymphocyte activation. Supported by MDA,Myasthenia Gravis Foundation Osserman postdoctoral fellow.J.W.McLaughlin postdoctoral fellow.

AB - Treatment of mice with established autoimmunity to acetylcholine receptor (AChR) with interferon a (EFNα) suppressed experimental autoimmune myasthenia gravis (EAMG) (Shenoy et al, J. Immunology, 154:6203, 1995). To study the therapeutic efficacy of IFNα after the established clinical signs, we treated mice with established EAMG with mouse IFNα (mIFNα) or human recombinant IFNα (HurlFNα). In experiment I, mIFNα ICPU and in experiment II, HurlFNα 104 U was ?iven intraperitoneal 3 times a week for 6 weeks. In experiment 1,6 of 8 (33%) mice had a complete clinical remission or significant improvement in IFNα group, while only 1 of 17 (6%) mice improved in PBS group, p=0.047; more mice died or worsened in PBS group (11/17) compared to IFNα group (8/18); In experiment II, 7 of 16 (44%) mice had a complete remission or significant improvement in IFNα group, in contrast to only 1 of 14 (7%) in PBS group, p=0.027; also more mice died or worsened in PBS group (6/14) than in IFNα group (4/16). IFNα treatment reduced the MHC class II expression on peripheral blood lymphocytes, and lowered the serum IFNγ level. IFNα in vitro also suppressed AChR and its dominant peptide a!46-162 specific lymphocyte proliferation. Therefore, IFNα, one of the very few treatments which exerts a therapeutic effect on EAMG, is associated with down regulation of IFNγ, MHC class II, and lymphocyte activation. Supported by MDA,Myasthenia Gravis Foundation Osserman postdoctoral fellow.J.W.McLaughlin postdoctoral fellow.

UR - http://www.scopus.com/inward/record.url?scp=33748896986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748896986&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -